"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 3 | 5 |
| 2000 | 5 | 2 | 7 |
| 2001 | 3 | 4 | 7 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 4 | 7 |
| 2004 | 3 | 4 | 7 |
| 2005 | 3 | 3 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 2 | 5 |
| 2010 | 1 | 6 | 7 |
| 2011 | 5 | 3 | 8 |
| 2012 | 6 | 1 | 7 |
| 2013 | 5 | 7 | 12 |
| 2014 | 8 | 8 | 16 |
| 2015 | 7 | 5 | 12 |
| 2016 | 4 | 2 | 6 |
| 2017 | 5 | 1 | 6 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 4 | 2 | 6 |
| 2021 | 4 | 3 | 7 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 3 | 4 |
| 2025 | 7 | 2 | 9 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis. Mult Scler. 2026 Aug; 32(9):972-984.
-
The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Osimertinib activates a TGF-?2-dependent secretory program that drives lung adenocarcinoma progression. J Clin Invest. 2026 02 02; 136(3).
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Dual Targeting of Orphan Nuclear Receptors NR4A1 and NR4A2 for Nonhormonal Endometriosis Therapy. Endocrinology. 2025 Oct 09; 166(11).
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities. Nat Chem Biol. 2025 Dec; 21(12):1938-1947.
-
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11; 24(1):175.
-
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precis Oncol. 2025 May; 9:e2500047.